Prevalence and correlates of diabetic peripheral neuropathy in a Saudi Arabic population: A cross-sectional study

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Wang, Dong D ^a   Bakhotmah, Balkees A ^b   Hu, Frank B ^a,c   Ali Alzahrani, Hasan ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CREATININE; GLUCOSE; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT;

ABDOMINAL OBESITY; ADULT; AGED; ANESTHESIA (SENSORY DYSFUNCTION); ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY HEIGHT; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; CORRELATIONAL STUDY; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIABETIC PERIPHERAL NEUROPATHY; DISEASE DURATION; DRUG USE; ETHNIC GROUP; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; LEUKOCYTE COUNT; LIGHT TOUCH PERCEPTION; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; NEUROLOGICAL DIAGNOSTIC DEVICE; NEUROTHESIOMETER; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCEPTION DISORDER; PREVALENCE; RISK ASSESSMENT; SAUDI ARABIA; SAUDI ARABIC PEOPLE; SEMMES WEINSTEIN MONOFILAMENT; SEX DIFFERENCE; SMOKING; TOUCH; VIBRATION SENSE; WAIST CIRCUMFERENCE; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; MIDDLE AGED; MULTICENTER STUDY; OBESITY, ABDOMINAL;

AGED; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY, ABDOMINAL; PREVALENCE; SAUDI ARABIA;

EID: 84906961714     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106935     Document Type: Article

References (47)

1. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, et al. (2005) Diabetic neuropathies a statement by the American Diabetes Association. Diabetes Care 28: 956-962.
2. Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA (2003) The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 26: 1790-1795.
3. (1995) The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 122: 561-568.
4. Morkrid K, Ali L, Hussain A (2010) Risk factors and prevalence of diabetic peripheral neuropathy: A study of type 2 diabetic outpatients in Bangladesh. Int J Diabetes Dev Ctries 30: 11-17.
5. Sone H, Mizuno S, Yamada N (2005) Vascular risk factors and diabetic neuropathy. N Engl J Med 352: 1925-1927; author reply 1925-1927.
6. Adler AI, Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, et al. (1997) Risk factors for diabetic peripheral sensory neuropathy: results of the Seattle Prospective Diabetic Foot Study. Diabetes Care 20: 1162-1167.
7. International Diabetes Federation (2013) Diabetes Atlas. Sixth Edition International Diabetes Federation.
8. Al-Mahroos F, Al-Roomi K (2007) Diabetic neuropathy, foot ulceration, peripheral vascular disease and potential risk factors among patients with diabetes in Bahrain: a nationwide primary care diabetes clinic-based study. Ann Saudi Med 27: 25-31.
9. Jambart S, Ammache Z, Haddad F, Younes A, Hassoun A, et al. (2011) Prevalence of Painful Diabetic Peripheral Neuropathy among Patients with Diabetes Mellitus in the Middle East Region. Journal of International Medical Research 39: 366-377.
10. Katulanda P, Ranasinghe P, Jayawardena R, Constantine GR, Sheriff MH, et al. (2012) The prevalence, patterns and predictors of diabetic peripheral neuropathy in a developing country. Diabetol Metab Syndr 4: 21.
11. Elhadd TA, Al-Amoudi AA, Alzahrani AS (2007) Epidemiology, clinical and complications profile of diabetes in Saudi Arabia: a review. Ann Saudi Med 27: 241-250.
12. Halawa MR, Karawagh A, Zeidan A, Mahmoud AE, Sakr M, et al. (2010) Prevalence of painful diabetic peripheral neuropathy among patients suffering from diabetes mellitus in Saudi Arabia. Curr Med Res Opin 26: 337-343.
13. World Health Organization (2000) Obesity: preventing and managing the global epidemic. World Health Organization technical report series 894.
14. Cuddy ML (2005) Treatment of hypertension: guidelines from JNC 7 (the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 1). J Pract Nurs 55: 17-21; quiz 22-13.
15. Bracewell N, Game F, Jeffcoate W, Scammell BE (2012) Clinical evaluation of a new device in the assessment of peripheral sensory neuropathy in diabetes. Diabet Med 29: 1553-1555.
16. Kamei N, Yamane K, Nakanishi S, Yamashita Y, Tamura T, et al. (2005) Effectiveness of Semmes-Weinstein monofilament examination for diabetic peripheral neuropathy screening. J Diabetes Complications 19: 47-53.
17. Boulton AJM, Armstrong DG, Albert SF, Frykberg RG, Hellman R, et al. (2008) Comprehensive Foot Examination and Risk Assessment: A report of the Task Force of the Foot Care Interest Group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Diabetes Care 31: 1679-1685.
18. Organization WH (2006) Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation.
19. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on Detection, Evaluation, and Treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA: the journal of the American Medical Association 285: 2486.
20. Ubbink JB, Hayward Vermaak W, Bissbort S (1991) Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. Journal of Chromatography B: Biomedical Sciences and Applications 565: 441-446.
21. Myers GL, Miller WG, Coresh J, Fleming J, Greenberg N, et al. (2006) Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clinical Chemistry 52: 5-18.
22. Macy EM, Hayes TE, Tracy RP (1997) Variability in the measurement of Creactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clinical Chemistry 43: 52-58.
23. Said G (2007) Diabetic neuropathy-a review. Nature Clinical Practice Neurology 3: 331-340.
24. Jambart S, Ammache Z, Haddad F, Younes A, Hassoun A, et al. (2011) Prevalence of painful diabetic peripheral neuropathy among patients with diabetes mellitus in the Middle East region. J Int Med Res 39: 366-377.
25. Gregg EW, Sorlie P, Paulose-Ram R, Gu Q, Eberhardt MS, et al. (2004) Prevalence of Lower-Extremity Disease in the US Adult Population$ 40 Years of Age With and Without Diabetes 1999-2000 National Health and Nutrition Examination Survey. Diabetes Care 27: 1591-1597.
26. Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, et al. (2010) Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 33: 2285-2293.
27. Dyck PJ, Davies JL, Clark VM, Litchy WJ, Klein CJ, et al. (2006) Modeling chronic glycemic exposure variables as correlates and predictors of microvascular complications of diabetes. Diabetes Care 29: 2282-2288.
28. Dyck PJ, Davies JL, Wilson DM, Service FJ, Melton LJ, 3rd, et al. (1999) Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes Care 22: 1479-1486.
29. De Block CE, De Leeuw IH, Van Gaal LF (2005) Impact of overweight on chronic microvascular complications in type 1 diabetic patients. Diabetes Care 28: 1649-1655.
30. Després J-P, Lemieux I (2006) Abdominal obesity and metabolic syndrome. Nature 444: 881-887.
31. Katsilambros NL, Boulton AJ, Tentolouris N, Kokkinos A, Liatis S (2011) Autonomic neuropathy in diabetes mellitus and obesity: an update. Exp Diabetes Res 2011: 607309.
32. Ylitalo KR, Sowers M, Heeringa S (2011) Peripheral Vascular Disease and Peripheral Neuropathy in Individuals With Cardiometabolic Clustering and Obesity National Health and Nutrition Examination Survey 2001-2004. Diabetes Care 34: 1642-1647.
33. Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A (2008) Prevalence of Polyneuropathy in Pre-Diabetes and Diabetes Is Associated With Abdominal Obesity and Macroangiopathy: The MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 31: 464-469.
34. Tapp RJ, Shaw JE, de Courten MP, Dunstan DW, Welborn TA, et al. (2003) Foot complications in Type 2 diabetes: an Australian population-based study. Diabet Med 20: 105-113.
35. Vincent AM, Hinder LM, Pop-Busui R, Feldman EL (2009) Hyperlipidemia: a new therapeutic target for diabetic neuropathy. Journal of the Peripheral Nervous System 14: 257-267.
36. Tesfaye S, Selvarajah D (2012) Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev 28 Suppl 1: 8-14.
37. Maser RE, Steenkiste AR, Dorman JS, Nielsen VK, Bass EB, et al. (1989) Epidemiological correlates of diabetic neuropathy: report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 38: 1456-1461.
38. Herder C, Lankisch M, Ziegler D, Rathmann W, Koenig W, et al. (2009) Subclinical Inflammation and Diabetic Polyneuropathy: MONICA/KORA Survey F3 (Augsburg, Germany). Diabetes Care 32: 680-682.
39. Weigelt C, Rose B, Poschen U, Ziegler D, Friese G, et al. (2009) Immune mediators in patients with acute diabetic foot syndrome. Diabetes Care 32: 1491-1496.
40. Vinik AI, Erbas T, Casellini CM (2013) Diabetic cardiac autonomic neuropathy, inflammation and cardiovascular disease. J Diabetes Investig 4: 4-18.
41. Davis T, Yeap B, Davis W, Bruce D (2008) Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia 51: 562-566.
42. Dyck P, Kratz K, Karnes J, Litchy W, Klein R, et al. (1993) The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort The Rochester Diabetic Neuropathy Study. Neurology 43: 817-817.
43. Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, et al. (2006) Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 29: 2365-2370.
44. Thomas MC, MacIsaac RJ, Tsalamandris C, Power D, Jerums G (2003) Unrecognized anemia in patients with diabetes: a cross-sectional survey. Diabetes Care 26: 1164-1169.
45. Kim ES, Moon SD, Kim HS, Lim DJ, Cho JH, et al. (2011) Diabetic peripheral neuropathy is associated with increased arterial stiffness without changes in carotid intima-media thickness in type 2 diabetes. Diabetes Care 34: 1403-1405.
46. Feng Y, Schlosser FJ, Sumpio BE (2009) The Semmes Weinstein monofilament examination as a screening tool for diabetic peripheral neuropathy. J Vasc Surg 50: 675-682, 682 e671.
47. Picon AP, Ortega NR, Watari R, Sartor C, Sacco IC (2012) Classification of the severity of diabetic neuropathy: a new approach taking uncertainties into account using fuzzy logic. Clinics (Sao Paulo) 67: 151-156.